JP5986095B2 - コンジュゲートおよび分子イメージングにおけるそれらの用途 - Google Patents

コンジュゲートおよび分子イメージングにおけるそれらの用途 Download PDF

Info

Publication number
JP5986095B2
JP5986095B2 JP2013538264A JP2013538264A JP5986095B2 JP 5986095 B2 JP5986095 B2 JP 5986095B2 JP 2013538264 A JP2013538264 A JP 2013538264A JP 2013538264 A JP2013538264 A JP 2013538264A JP 5986095 B2 JP5986095 B2 JP 5986095B2
Authority
JP
Japan
Prior art keywords
bifunctional
group
composition
compound
radionuclide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013538264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501714A (ja
JP2014501714A5 (https=
Inventor
ラッセル バリンガー ジェイムズ
ラッセル バリンガー ジェイムズ
ベリー デイビッド
ベリー デイビッド
ジョン ブロワー フィリップ
ジョン ブロワー フィリップ
ヨンミン マ
ヨンミン マ
Original Assignee
キングス・カレッジ・ロンドン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キングス・カレッジ・ロンドン filed Critical キングス・カレッジ・ロンドン
Publication of JP2014501714A publication Critical patent/JP2014501714A/ja
Publication of JP2014501714A5 publication Critical patent/JP2014501714A5/ja
Application granted granted Critical
Publication of JP5986095B2 publication Critical patent/JP5986095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1033—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2013538264A 2010-11-11 2011-11-11 コンジュゲートおよび分子イメージングにおけるそれらの用途 Active JP5986095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1019118.7 2010-11-11
GB201019118A GB201019118D0 (en) 2010-11-11 2010-11-11 Conjugates and their uses in molecular imaging
PCT/GB2011/001599 WO2012063028A1 (en) 2010-11-11 2011-11-11 Conjugates and their uses in molecular imaging

Publications (3)

Publication Number Publication Date
JP2014501714A JP2014501714A (ja) 2014-01-23
JP2014501714A5 JP2014501714A5 (https=) 2014-12-25
JP5986095B2 true JP5986095B2 (ja) 2016-09-06

Family

ID=43431334

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538264A Active JP5986095B2 (ja) 2010-11-11 2011-11-11 コンジュゲートおよび分子イメージングにおけるそれらの用途

Country Status (7)

Country Link
US (1) US9138495B2 (https=)
EP (1) EP2637705B1 (https=)
JP (1) JP5986095B2 (https=)
AU (1) AU2011327931B2 (https=)
ES (1) ES2625829T3 (https=)
GB (1) GB201019118D0 (https=)
WO (1) WO2012063028A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098442B2 (en) 2003-03-05 2006-08-29 Raytheon Company Thin micropolarizing filter, and a method for making it
CN103561771B (zh) 2011-03-17 2019-01-04 伯明翰大学 重新定向的免疫治疗
JP7023604B2 (ja) 2013-10-31 2022-02-22 ベス・イスラエル・ディーコネス・メディカル・センター，インコーポレイテッド 近赤外蛍光造影バイオイメージング剤及びその使用方法
US11001562B2 (en) 2013-10-31 2021-05-11 Beth Israel Deaconess Medical Center Near-infrared fluorescent nerve contrast agents and methods of use thereof
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
JP7253762B2 (ja) * 2017-12-27 2023-04-07 慈濟大學 タンパク質を表面に発現させた小胞によるオートファジー細胞およびアポトーシス細胞への薬剤送達
US12440585B2 (en) 2023-09-12 2025-10-14 Curadel Surgical Innovations, Inc. Zwitterionic metal chelators
CN120590625A (zh) * 2024-11-06 2025-09-05 江苏申命医疗科技有限公司 一种放射性核素标记的聚合物、其制备方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU2865995A (en) 1995-06-14 1997-01-15 Regents Of The University Of California, The 3-hydroxy-2(1h)-pyridinone chelating agents
US8926945B2 (en) * 2005-10-07 2015-01-06 Guerbet Compounds comprising a biological target recognizing part, coupled to a signal part capable of complexing gallium
US8158804B2 (en) 2007-01-11 2012-04-17 Ge Healthcare As Chelating agents
WO2009021947A1 (en) * 2007-08-13 2009-02-19 Ge Healthcare As Chelators, paramagnetic chelates thereof and their use as contrast agents in magnetic resonance imaging (mri)
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Also Published As

Publication number Publication date
GB201019118D0 (en) 2010-12-29
EP2637705B1 (en) 2017-03-29
AU2011327931A2 (en) 2013-07-11
JP2014501714A (ja) 2014-01-23
EP2637705A1 (en) 2013-09-18
AU2011327931B2 (en) 2017-02-23
AU2011327931A1 (en) 2013-07-04
ES2625829T3 (es) 2017-07-20
US20140056810A1 (en) 2014-02-27
US9138495B2 (en) 2015-09-22
WO2012063028A1 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
JP5986095B2 (ja) コンジュゲートおよび分子イメージングにおけるそれらの用途
Chomet et al. State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET
JP6368745B2 (ja) プレターゲットキット、プレターゲット方法及びその使用試薬
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
RU2539915C2 (ru) Набор для предварительного придания направленности действия, способ и средства, применяемые в нем
CA2822693C (en) Radiolabled her2 binding peptides
Reissig et al. Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin
Moreau et al. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes
Vugts et al. Synthesis of phosphine and antibody–azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach
CN102316903A (zh) Pdgf-rbeta结合剂
US20150359913A1 (en) Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
Imberti et al. Enhancing PET signal at target tissue in vivo: dendritic and multimeric tris (hydroxypyridinone) conjugates for molecular imaging of αvβ3 integrin expression with gallium-68
CN119343151A (zh) 一种三功能化合物及其用途
Wiehr et al. Pharmacokinetics and PET imaging properties of two recombinant anti‐PSMA antibody fragments in comparison to their parental antibody
Ma et al. Macrobicyclic cage amine ligands for copper radiopharmaceuticals: a single bivalent cage amine containing two Lys3-bombesin targeting peptides
Ma et al. Gallium-68 complex of a macrobicyclic cage amine chelator tethered to two integrin-targeting peptides for diagnostic tumor imaging
Hazari et al. Synthesis of specific SPECT-radiopharmaceutical for tumor imaging based on methionine: 99mTc-DTPA-bis (methionine)
Krutzek et al. Design, synthesis, and biological evaluation of small-molecule-based radioligands with improved pharmacokinetic properties for imaging of programmed death ligand 1
Noor et al. Imaging somatostatin positive tumors with Tyr3-octreotate/octreotide conjugated to desferrioxamine B squaramide radiolabeled with either zirconium-89 or gallium-68
US20250339568A1 (en) Precursor and radiotracer for neuroendocrine theranostics
Feng et al. Development of a novel 99mTc-labeled folate derivative containing phenyl isonitrile to target folate receptor with reduced renal uptake
KR102374087B1 (ko) 면역 컨쥬게이트 및 그의 용도
Huynh The Evaluation of Radiometal Labeled Biomolecules for Imaging and Therapeutic Applications
WO2022156907A1 (en) Method and kit for labeling a biomolecule with one or more detectable labels, including a radiolabel
WO2022156908A1 (en) Method for preparing a lyophilized composition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160804

R150 Certificate of patent or registration of utility model

Ref document number: 5986095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250